Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma
Thomas Powles(St Bartholomew's Hospital), Sanjeev Mariathasan, Nicole N. Davarpanah(La Roche College), Daniel Castellano(Universidad Complutense de Madrid), Petros Grivas(Fred Hutch Cancer Center), Maha Hussain(University of Michigan), Siamak Daneshmand, Corey Carter(La Roche College), Zoe J. Assaf(La Roche College), Himanshu Sethi(Natera (United States)), Stéphane Oudard(Délégation Paris 5), Alexey Aleshin(Natera (United States)), Jürgen E. Gschwend(TUM Klinikum), Peter Albers(Düsseldorf University Hospital), Hiroyuki Nishiyama(Kyoto University), Joaquim Bellmunt(Radboud University Nijmegen), Viraj Degaonkar(La Roche College), Shruti Sharma(Natera (United States)), Yi Shi(Southern Medical University)
Cited by 128
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k